| Name | Title | Contact Details |
|---|
New Century Health delivers specialty care management solutions that leverage technology and evidence-based medicine at the point-of-care, with a focus on oncology and cardiology. Our services promote the most effective treatment, reduce variability, improve clinical outcomes, and optimize cost-effectiveness.
Alfie uses precision tests to determine the right combination of prescription medication and 1:1 health coaching to optimize your weight loss.
IncludeHealth is a digital health and performance company delivering next-generation musculoskeletal care and training. Offered through a monthly subscription, their platform provides a comprehensive digital suite that pairs HIPAA compliant cloud software with connected equipment, sensors and data to quantify and qualify human performance. This unique pairing provides breakthrough capabilities such as centralized and standardized protocols, outcomes-based data collection, autonomous instruction and documentation, and location agnostic delivery to produce better outcomes with lower costs. The proprietary technology at IncludeHealth has been recognized with 28 international innovation and health awards and is utilized in orthopedics, neuroscience, pediatric care, senior care, government, and general wellness facilities.
Saint Ann Retirement Center is a Oklahoma City, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Xenon Pharmaceuticals (NASDAQ:XENE) – a biopharmaceutical company with operations in Vancouver, BC, Canada and Boston, MA, U.S.A. – is committed to delivering innovative medicines to provide a brighter future for patients suffering from neurological disorders. At Xenon, we are advancing an exciting pipeline of neurology-focused therapies, with a particular emphasis on novel treatments for both adult and pediatric patients with epilepsy. XEN496 is currently being evaluated in the Phase 3 “EPIK” clinical trial in young patients with KCNQ2-DEE, a rare and severe form of childhood epilepsy. Late-stage development plans are also underway for our XEN1101 program, building upon the compelling data from the Phase 2b “X-TOLE” study in adult patients with focal epilepsy. We are also proud of the leading-edge science coming out of our discovery labs, with many early-stage research programs underway. In addition to Xenon`s proprietary programs, we have ongoing collaborations with our valued pharmaceutical partners. With a healthy balance sheet to support our growth plans, we continue to build a fully-integrated, premier neuroscience company with strong discovery, development, and commercial operations. Our employees are smart, passionate, dedicated, and driven by their incredibly important work to discover, develop, and deliver new medicines for patients in need. Building and maintaining a respectful, collaborative, inclusive, and productive culture is a priority for us. We are looking for great people who thrive in a fast-paced, dynamic work environment to join our team during this transformative time for Xenon.